Chasalow, Scott D.
Bristol-Myers Squibb (United States)
3 papers on CoChatORCID 0000-0003-1513-0249
Most cited papers
- Verified
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 534
- Verified
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Wang, L., Saci, A., Szabo, P. M., Chasalow, S. D., Castillo-Martin, M., Domingo-Domenech, J., Siefker-Radtke, A., Sharma, P., Sfakianos, J. P., Gong, Y., et al. (2018) · Nature Communications
Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments
Cited by 313
- Verified
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Choueiri, T. K., Fishman, M. N., Escudier, B., McDermott, D. F., Drake, C. G., Kluger, H., Stadler, W. M., Perez-Gracia, J. L., McNeel, D. G., Curti, B., et al. (2016) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment
Cited by 295
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free